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Abstract
Background: Highly variable results of topical diphenylcyclopropenone (DPCP) in the treatment
of alopecia areata have been reported so far. The purposes of the present study were to evaluate
the efficacy and tolerability of DPCP treatment in severe alopecia areata.
Methods: Twenty-eight patients (16 female and 12 male, 10–35 years old, mean age 25 years) with
extensive alopecia areata were enrolled in an open-label clinical trial. After sensitization with 2%
DPCP, progressively higher concentrations beginning at 0.001% were applied weekly for 6 months
to one side of the scalp, after which, if terminal hair growth was noted, the entire scalp was then
treated under the same weekly protocol. The maximum concentration of DPCP in acetone was 2%.
Results: Twenty-seven of 28 patients completed therapy. The overall response rate was 81.5%
(22/27), complete remission (90%-100% terminal hair re-growth) was obtained 22.2% (6/27) and
partial remission (10%-90% terminal hair re-growth) in 59.3% (16/27). In all patients an eczematous
reaction consisting of erythema, itching, and scaling at the site of application were observed. During
therapy, other side effects including, occipital lymphadenopathy 40.7% (11/27), severe eczema/
blister formation 40.7% (11/27), hyperpigmentation 18.5% (5/27) were observed, but no
hypopigmentation, vitiligo, contact urticaria, and erythema multiforme-like reaction were seen in
the patients. Nineteen of 27 (70.4%) patients had at least one side effect, other than eczematous
reaction. Notably, partial recurrence was observed in 50.9% (13/22) of these patients after 6 to 12
months of follow-up. During the follow-up time the maintenance DPCP immunotherapy was
continued.
Conclusion: Topical DPCP treatment for alopecia areata is an effective therapy with a slightly high
relapse rate during bilateral maintenance treatment. According to the author's knowledge this is
the first experience with DPCP in Iran.
Background
Dermatosis of the scalp such as alopecia areata (AA) are a
burden for many patients and often resistant, even to
extensive therapy [1-4]. Furthermore, treatment results
can be difficult to interpret because of spontaneous remis-
sions and recurrences, as well as the use of several thera-
pies simultaneously, such as tretinoin creams, minoxidil
lotions and zinc supplementation [4]. Topical and intra-
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lesional corticosteroid therapy is frequently tried, but the
benefit of such treatment is often questionable or tempo-
rary. Systemic corticosteroid treatment may be effective in
some cases, but the maintenance dose needed is often
high [4,5]. Some success, has been reported with anthra-
lin, but results seem variable [6,7]. Other therapies which
have been tried, with variable success, include minoxidil
[8,9], cyclosporine [10-12], alpha-interferon [13], and
acupuncture [14].
Topical immunotherapy has been used for more than 10
years for the treatment of severe AA and various contact
allergens such as dinitrochlorobenzene (DNCB), squaric
acid dibutylester (SADBE), and diphenylcyclopropenone
(DPCP) have determined re-growth of hair in patients
with AA [15-17].
The effectiveness of topical immunotherapy with AA has
been demonstrated in several reports, although the
response rate varied greatly from 4% to 85% [18]. The
present study was performed as an open-label clinical trial
to evaluate the efficacy and tolerability of topically admin-
istered DPCP in patients with extensive AA. In addition,
the clinical response with prognostic factors was corre-
lated and assessed the patients' response after a follow-up
of 6 to 12 months, in which bilateral DPCP maintenance
treatment was continued.
Methods
During 2 years between April 2001 and May 2003 at the
Department of Dermatology, Saadi Hospital, Shiraz Uni-
versity of Medical Sciences, 28 patients (12 men, 16
women) with severe AA (> 40% scalp hair loss) were
enrolled in an open-label clinical trial. Their ages ranged
from 10 to 35 years (mean, 25 years). The DPCP used
(Acros Organics, New Jersey, USA) 98% pure, was dis-
solved in acetone. Informed consent was obtained.
Women of childbearing age were required to use a reliable
form of birth control. Individuals with AA were ineligible
for DPCP treatment if they presented with less than 40%
scalp involvement, the age less than 10 years, significant
cardiovascular disease, pregnancy, or serious intercurrent
medical illnesses. In brief, sensitization was performed
with a 2% solution of DPCP applied to an area of 5× 5 cm
on one side of the scalp. Two weeks following sensitiza-
tion, treatment was started by weekly ipsilateral applica-
tions of incremental concentrations of DPCP (between
0.001% and 2%) adjusted to the patient's reactivity to the
contact allergen. The aim was to maintain mild contact
eczema and itch for about 48 hours after application.
Patients were instructed to avoid direct sun exposure of
the scalp and not to wash the scalp for 48 hours after each
application. The opposite half of the scalp served as a con-
trol to rule out possible spontaneous remission. Once hair
re-growth occurred on the treated side, the applications
were extended over the entire scalp. The overall duration
of therapy varied from 6 to 12 months. The patients, who
achieved clinically significant re-growth, were under fol-
low-up of 6–12 months, with ongoing maintenance
DPCP immunotherapy.
The types of AA before treatment were classified as fol-
lows: (1) multilocular AA including ophiatic type with >
40% loss of scalp hair; (2) subtotal or total AA; (3) AA par-
tim universalis (loss of all scalp hair with some body hair
left) or universalis (loss of all scalp and body hair).
According to the response to topical DPCP immuno-
therapy, patients were grouped into 3 categories: no hair
re-growth (< 10% terminal hair), partial hair re-growth
(10–90% terminal hair) and complete hair re-growth
(90–100% terminal hair).
Efficacy evaluation was performed with clinical examina-
tion. If no re-growth was observed within 6 months of
treatment, the patient was considered to be a non-
responder and was dropped from the trial.
In all patients, the following laboratory tests were per-
formed at baseline, every 3 months during treatment and
after treatment: complete blood cell count; chemistry pro-
file; urinalysis; levels of thyroid hormones (free tri-
iodothyronine, free thyroxine, thyroid stimulating hor-
mone); fasting blood sugar; and antinuclear antibody
titres (ANA). Other laboratory tests such as anti-gastric
parietal cells, anti-thyroglobulin and anti-smooth muscle
antibody titres were not done, because of loss of these
capabilities in our institute.
The influence of the following factors on the outcome of
topical immunotherapy were investigated: sex, age at
onset, atopy, disease duration before treatment, type of
AA, presence of nail changes, presence of naevus simplex,
and family history of AA and other auto-immune disor-
ders such as diabetes mellitus (DM) and thyroid diseases.
To assess any correlations between the above mentioned
parameters the X2 test was used.
Results
Twenty-seven out of 28 patients completed the treatment.
The demographic and clinical data of the patients
included in the study are summarized in table 1 and 2.
Table 1: Demographic data
Number of patients 27
Sex M/F 12/15
Age (range, mean) 10–35, 25 years
Disease duration before treatment (range, mean) 0.58–28, 5.82 yearsBMC Dermatology 2005, 5:6 http://www.biomedcentral.com/1471-5945/5/6
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Disease duration before treatment ranged from 0.58 (7
months) to 28 years. The duration of therapy ranged from
6 to 24 months, including long-term patients with
repeated DPCP treatment for maintaining hair re-growth.
Overall 81.5% (22 of 27 patients) responded to therapy:
22.2% (6 of 27 patients) achieved complete hair re-
growth (90–100% terminal hair), and 59.3% (16 of 27
patients) had partial hair re-growth (10–90% terminal
hair). Five patients had no hair re-growth (18.5%). Of the
22 patients with complete and partial remission, 13
(50.9%) suffered a relapse either simultaneously mainte-
nance treatment of follow-up or following termination of
therapy. No abnormalities were detected on baseline and
follow-up laboratory data in these patients.
Side effects following sensitization were seen in 19 of 27
patients (70.4%): occipital lymphadenopathy in 40.7%
(11 of 27 patients), severe eczema/blister formation in
22.2% (6 of 27 patients), and hyperpigmentation in
18.5% (5 of 27 patients). No cases of hypopigmentation,
vitiligo, contact urticaria, and erythema multiforme-like
reaction were observed. The therapeutically induced mild
contact eczema with itching was not considered as adverse
effects.
Discussion
Topical immunotherapy, using DPCP, is currently consid-
ered the most effective mode of treatment. However, the
way in which DPCP operates on hair follicles in AA still
remains to be elucidated. Vascular endothelial growth fac-
tor (VEGF), essential for angiogenesis and vascular perme-
ability, may be responsible for maintaining proper
vasculature around hair follicles, and several studies pro-
vide evidence that apoptosis is a central element in the
regulation of hair follicle and vascular regression [19].
Moreover, topical immunotherapy considerably alters the
peribulbar CD4/CD8 ratio in human and experimental
animal studies, restoring a condition close to normal
scalp skin [19,20].
In the present study, growth of terminal hair on the entire
scalp was achieved totally in 81.5% of patients with AA
after 6–12 months of treatment with DPCP. This results
are less than those reported by Cotellessa et al [18] who
observed a 48% complete success rate in a series of 52
patients, and those of Weise et al [21] and Van der Steen
et al [22] who detected 40% and 50.4% complete re-
growth in 124 and 139 patients, respectively (complete
hair re-growth in the present study was 22.2%). In other
reports, however, the percentage of success greatly varied
from 4% to 85% [17,21,23-25]. The discrepancy of
response rates may be due to the number of patients in
clinical trials; the type, duration, and severity of the AA;
and different methods of assessing clinical efficacy.
In the present study, concomitant spontaneous re-growth
of eyebrows and body could be observed in approxi-
mately half of the successfully treated patients, which are
similar to those reported by Cotellessa et al [18]. Nine of
27 patients had positive family history of atopy, but no
significant correlations between its frequency and treat-
ment response revealed (P = 0.07). Also, positive per-
sonal/family history of thyroid disease, atopy, and
diabetes mellitus (DM); sex; age of patients; type of AA;
and duration of disease before treatment had no signifi-
cant correlations with treatment response (P > 0.05). In
addition, the X2  test revealed significant correlation
between the presence of naevus simplex (salmon patch)
on the posterior neck and less favorable treatment
response (P = 0.03). The same correlation between the
presence of nail changes (such as pitting, ridging,
leukonychia punctata, brittleness, "red spotted lunula",
"sandpaper nails", and onychomadesis) and less favora-
ble response rate was detected (P = 0.02). Remarkably,
with regard to patients' follow-up with ongoing mainte-
nance therapy in patients with significant hair re-growth,
partial recurrences of AA were observed in about one-half
of the patients.
Wiesman et al. referred to the risks of relapse at long-term
follow-up. After 35 months of follow-up, 62.6% of the
subjects who had been successfully treated experienced a
relapse, and this risk was not influenced by the implemen-
tation of maintenance therapy [26]. This result is in
Table 2: Clinical data
Type of AA
(1) Multi-locular including ophiatic type (>40% of 
scalp hair loss)
11/27 (40.7%)
(2) Subtotal, total 5/27 (18.6%)
(3) Universalis, partim universalis 11/27 (40.7%)
Positive family history of:
AA 10/27 (37%)
Thyroid disease 7/27 (6%)
DM 9/27 (33.3%)
Positive personal history of:
Thyroid disease 3/27 (11.1%)
DM None
Presence of nail changes 16/27 (59.3%)
Presence of naevus simplex on the posterior neck 11/27 (40.7%)
Circulating ANA NoneBMC Dermatology 2005, 5:6 http://www.biomedcentral.com/1471-5945/5/6
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agreement with the present study. But, other investigators
believe that if this result could be reproduced in other
studies, the patient could stop treatment when hair re-
growth was complete because maintenance treatment
would be of no use [27].
Among the investigated "prognostic factors" for the out-
come of DPCP treatment, which have formerly been stud-
ied with variable results [21,25,28], only the presence of
naevus simplex and nail changes were found to be of
significance.
The main side effects observed during therapy with rela-
tively high frequency were severe eczema/bullous forma-
tion, occipital lymphadenopathy, and
hyperpigmentation. In none of the patients hypo-pigmen-
tation or vitiligo were observed.
A 12-year-old patient with alopecia totalis before treatment Figure 1
A 12-year-old patient with alopecia totalis before treatment.
The same patient 4-weeks after treatment Figure 2
The same patient 4-weeks after treatment.
After 20-weeks of treatment (bilateral treatment started on  12-weeks, no photo available) Figure 3
After 20-weeks of treatment (bilateral treatment started on 
12-weeks, no photo available).
After 24-weeks of treatment (right view) Figure 4
After 24-weeks of treatment (right view).BMC Dermatology 2005, 5:6 http://www.biomedcentral.com/1471-5945/5/6
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Conclusion
The study findings are in agreement with former studies
showing the efficacy of topical immunotherapy with
DPCP in the treatment of severe AA, but with a slightly
high relapse rate during bilateral maintenance treatment.
According to the author's knowledge this is the first expe-
rience with DPCP in Iran.
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